Cloud-Clone expands multiplex assay lineup for flow-cytometry labs

Cloud-Clone Corp. says it is broadening its flow-based CBA multiplex assay portfolio to help life-science researchers measure more biomarkers from limited samples. The company is targeting global demand across immunology, oncology, neuroscience and other fields with pre-validated panels and custom assay development.

Why it matters: - Sample scarcity remains a major constraint in biomedical research, especially in studies that need many biomarkers from one limited specimen. - Multiplex assays can replace multiple single-analyte tests, saving sample volume and increasing throughput for research in immunology, cancer, neuroscience, metabolism and cell therapy. - Cloud-Clone is positioning its flow-based CBA platform as a lower-barrier option for labs that already use flow cytometry instruments.

What happened: - Cloud-Clone Corp. outlined a global multiplex assay offering built around flow-based CBA technology. - The company said the portfolio is designed for high-throughput multianalyte detection across life-science research applications. - Cloud-Clone also said its multiplex products are aimed at researchers working in tumour immunology, organoids, cell-based therapies, metabolic disorders and neuroscience.

The details: - Flow-based CBA is compatible with existing flow-cytometry instruments, avoiding the need for dedicated new hardware. - The company says measuring 10 protein biomarkers with flow-based CBA uses about one-tenth the sample volume required for parallel single-plex ELISA. - Cloud-Clone says the approach can conserve up to 90% of starting material. - The company compares its flow-based CBA approach with Luminex xMAP and MSD electrochemiluminescence as other common multiplex methods. - Cloud-Clone says its library includes more than 7,000 analytes across more than 10 species, including human, rat, mouse, guinea-pig, rabbit, chicken, dog, sheep, pig and cattle. - The portfolio includes more than 350 validated fixed panels across autoimmune disorders, neuroscience, cardiovascular disease, endocrinology, gastroenterology, respiratory disease, bone metabolism and oncology. - Custom development is available for rare species and harder-to-measure targets, including hormones and small molecules. - The company says custom panels can combine any analytes from the 7,000-plus target library and can range from 1 to 8 markers per assay. - For orders with four analytes or fewer, Cloud-Clone says delivery takes 1 to 3 weeks. - The disease-focused panels include a mouse 7-plex autoimmunity panel, a human 12-plex inflammatory panel, a bone-metabolism 13-plex panel, diabetes and endocrinology panels, neuroscience panels, cardiovascular panels, gastroenterology panels, respiratory panels and oncology panels. - Specific examples include a liver-fibrosis 6-plex panel, an asthma 8-plex panel, an Alzheimer’s- and Parkinson’s-relevant 10-plex panel and an angiogenesis-focused 8-plex panel. - Cloud-Clone said its product set supports disease-mechanism studies, pharmacodynamic work and safety-evaluation projects. - The company said it provides multiplex assay kits, immunoassay reagents, ELISA kits, primary cells and CRO services. - Cloud-Clone directs customers to more information. - The company also listed social accounts on LinkedIn, Instagram, TikTok and X.

Between the lines: - Cloud-Clone is using a broad catalog and custom-development claims to compete in a crowded reagents market. - The strategy appears aimed at labs that want multiplexing without new capital investment in specialized platforms. - The emphasis on pre-validated disease panels suggests a push to shorten assay selection time for researchers.

What's next: - Cloud-Clone said it will keep expanding its validated flow-CBA multiplex portfolio. - The company said it will continue refining assay performance and broadening species and target coverage. - Future demand is expected to rise as precision medicine, translational research and personalized-therapy studies expand their use of multiplex detection.

The bottom line: - Cloud-Clone is betting that flexible, sample-efficient multiplex testing will remain a core workflow as researchers look for more data from fewer specimens.